- Home
- KSS vs PVLA Comparison
KSS vs PVLA Comparison
Compare KSS & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KSS | PVLA |
|---|---|---|
| Founded | 1962 | 2015 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | KSS | PVLA |
|---|---|---|
| Price | $12.49 | $112.54 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $15.31 | ★ $162.06 |
| AVG Volume (30 Days) | ★ 5.2M | 279.8K |
| Earning Date | 03-10-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ 142.86 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.09 | N/A |
| P/E Ratio | $5.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.04 | $18.23 |
| 52 Week High | $25.22 | $151.18 |
Technical Indicators
Market Signals| Indicator | KSS | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 33.83 | 46.19 |
| Support Level | $12.04 | $109.36 |
| Resistance Level | $16.95 | $147.47 |
| Average True Range (ATR) | 0.84 | 7.76 |
| MACD | 0.07 | -2.84 |
| Stochastic Oscillator | 9.81 | 8.85 |
Price Performance
Historical ComparisonAbout KSS Kohl's Corporation
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.